Can Fite BioPharma Ltd (CANF)

[~MulaGreen~]

CANF CCNews...


Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it will conduct a conference call with investors to review the results of its Phase II exploratory NAFLD/NASH study with Namodenoson which achieved its primary and secondary efficacy endpoints, while showing continued safety.
Top-line results from the Phase II double-blind, placebo-controlled, dose-finding efficacy and safety study which enrolled 60 patients with non-alcoholic fatty liver disease (NAFLD) with or without non-alcoholic steatohepatitis (NASH), were announced on April 7, 2020 and can be found here.
Call Information
Date: Thursday, April 16, 2020
Time: 4:05 p.m. ET
Dial-in U.S.: 1-877-423-9813
Dial-in Israel: 1-201-689-8573
Conference ID: 13702174
Webcast: http://public.viavid.com/index.php?id=139178

https://finance.yahoo.com/news/fite-conduct-investor-call-review-110000260.html